Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
3.220
-0.100 (-3.01%)
Dec 3, 2024, 12:49 PM EST - Market open
Soligenix Revenue
Soligenix had revenue of $364.18K in the twelve months ending September 30, 2024, down -62.09% year-over-year. In the year 2023, Soligenix had annual revenue of $839.36K, down -11.55%.
Revenue (ttm)
$364.18K
Revenue Growth
-62.09%
P/S Ratio
10.89
Revenue / Employee
$24,279
Employees
15
Market Cap
8.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Precipio | 17.41M |
Zhongchao | 17.41M |
NeuroMetrix | 3.77M |
FOXO Technologies | 1.34M |
Virax Biolabs Group | 84.87K |
SNGX News
- 1 day ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 14 days ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 18 days ago - Soligenix to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 19 days ago - Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - PRNewsWire
- 25 days ago - Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - PRNewsWire
- 6 weeks ago - Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - PRNewsWire
- 6 weeks ago - Soligenix Invited to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PRNewsWire